Shareholder Alert: Robbins LLP Announces Gossamer Bio, Inc. (GOSS) Sued for Misleading Shareholders

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites.
Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. For avoidance of any doubts and to make it easier, you may consider any links to external websites as sponsored links. Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Shareholder rights law firm Robbins LLP announces that a purchaser of Gossamer Bio, Inc. (NASDAQ: GOSS) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 8, 2019 and December 13, 2019, as well as violations of the Securities Act of 1933 pursuant to its February 2019 initial public offering (“IPO”). Gossamer is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapeutics. Gossamer’s leading product is GB001, a DP2 antagonist drug for the treatment of asthma.

If you suffered a loss as a result of Gossamer’s misconduct, click here.

Gossamer Bio, Inc. (GOSS) Accused of Misleading Shareholders

According to the complaint, on February 8, 2019, Gossamer held its IPO offering approximately 17.25 million shares at $16.00 per share and raising $256 million in proceeds. In Gossamer’s IPO offering materials, the Company claimed that GB001 had not met its primary endpoint for improvement in a phase 2 trial due to “study design and execution issues related to patient selection” and assured that Novartis, who had a product like GB001, had a successful phase 2 trial that clinically validated DP2 antagonism. Gossamer maintained these statements throughout the class period, allowing its stock to trade as high as $27.15 per share. However, on December 16, 2019, Novartis announced it was terminating the development of its similar DP2 antagonist drug for asthma after it failed a pair of phase 3 clinical trials. On this news, Gossamer’s stock plummeted 37% to close at $15.96 per share. The stock has yet to recover.

Gossamer Bio, Inc. (GOSS) Shareholders Have Legal Options

Contact us to learn more: Leo Kandinov (800) 350-6003 [email protected] Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Leonid Kandinov

Robbins LLP

5040 Shoreham Place

San Diego, CA 92122

[email protected]

(619) 525-3990 or Toll Free (800) 350-6003

www.robbinsllp.com